InsidersTradesSigma
Browse the full record of transactions filed by Ronsheim Matthew, Dirigeant. Officer active across 1 companies, notably Entasis Therapeutics Holdings Inc.. Cumulatively, 6 reports have been logged. The latest transaction was disclosed on 18 January 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
6 of 6 declarations
Matthew Ronsheim is Chief, Pharma Sciences & MFG. at Entasis Therapeutics Holdings Inc. He is responsible for pharmaceutical sciences and manufacturing within the company. His technical expertise is crucial for developing high-quality products.